Related Experiment Videos
Reboxetine: a preliminary report on its use through the Special Access Program.
Sidney H Kennedy1, Raymond W Lam, Nicole L Cohen
1University Health Network, Department of Psychiatry, University of Toronto, Toronto, Ont. sidney.kennedy@uhn.on.ca
Journal of Psychiatry & Neuroscience : JPN
|December 21, 2002
Summary
Reboxetine effectively treated refractory depression in 56% of patients. This antidepressant shows promise for individuals resistant to other treatments, offering a new therapeutic option.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Medicine
Background:
- Depressive disorders represent a significant global health burden.
- Treatment resistance is common in patients with depression.
- Novel therapeutic agents are needed for refractory depression.
Purpose of the Study:
- To evaluate the effectiveness and tolerability of reboxetine.
- To assess reboxetine use under Canada's Special Access Program.
- To investigate reboxetine in treatment-resistant depressive disorders.
Main Methods:
- Retrospective, open-label study design.
- Involved outpatients with depressive disorders across six Canadian academic settings.
- Utilized the Clinical Global Impression (CGI) scales for assessment.
Main Results:
- Reboxetine treatment led to significant improvement in 56% of patients.
- The majority of patients received reboxetine doses between 4-10 mg.
- 44% of patients had moderate to severe depression at baseline.
Conclusions:
- Reboxetine demonstrated clinically meaningful effectiveness in reducing depression severity.
- The drug is a viable option for patients with treatment-resistant depression.
- Reboxetine offers a valuable role in managing refractory depressive disorders.